Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Adopting more stringent guidelines in the UK could reduce food-related greenhouse gas emissions by 70% and reduce diet-related deaths by more than 100,000 a year

Selection of foods layed out on a dark surface

Researchers led by Dr Marco Springmann from the Nuffield Department of Population Health, have found that most dietary recommendations provided by national governments are not compatible with global environmental and health targets such as the Paris Climate Agreement and the Sustainable Development Goals. Recommending stricter limits on meat and dairy, and encouraging increased consumption of whole grains, fruits and vegetables, legumes, and nuts would be both healthier and lower in environmental impacts, their study found.

A team at the LEAP (Livestock, Environment and People) programme at the University of Oxford, and at Harvard, Tufts and Adelaide universities, looked at dietary recommendations from 85 countries. The paper, published today in The BMJ, is the first of its kind to analyse both the health and environmental outcomes of national dietary guidelines around the world.

The researchers modelled the adoption of guidelines at both the national and global level, and compared the impacts to global environmental and health targets that governments have agreed to and that are related to diets. These include, for example, the goal to reduce premature mortality from non-communicable diseases by a third, and the agreement to limit global warming to below 2 degrees Celsius.

The full story is available on the Nuffield Department of Population Health website

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.